Dissecting the peptide motifs controlling coronavirus infections
剖析控制冠状病毒感染的肽基序
基本信息
- 批准号:10648391
- 负责人:
- 金额:$ 22.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-10 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAntiviral AgentsBindingBiochemicalCOVID-19 vaccineCell membraneCell surfaceCellsCellular StructuresCoat Protein Complex ICodeCommunicationComplexCoronavirusCoronavirus InfectionsCytoplasmCytoplasmic TailDataE proteinEndoplasmic ReticulumEndosomesFoundationsGoalsHumanInfectionIntegration Host FactorsKnowledgeLaboratoriesMembraneMembrane ProteinsMethodsMolecular ChaperonesMusOrganellesPathogenicityPathway interactionsPeptidesProcessProteinsRecombinantsRecyclingResearchSiteSystemVesicleViralViral Matrix ProteinsViral ProteinsVirionVirusVirus DiseasesVirus-like particlecomparativeimprovedintracellular protein transportknockout genenovel coronavirusparticlepharmacologicprotein transportrecombinant virussorting nexinstraffickingvesicle transportvirus host interaction
项目摘要
PROJECT SUMMARY/ABSTRACT
This proposal aims to evaluate coronavirus assembly and egress. These late infection stages are
understudied relative to coronavirus entry replication. Additional research is necessary to
reveal how host cell machineries facilitate assembly and egress. Therefore, this proposal
specifically focuses on coronavirus membrane proteins, their interactions with host cell
components, and the relevance of these contacts to efficient virion formation and emergence
from infected cells. Guided by biochemical and protein structural data documenting interfaces
between viral peptide motifs and host coatomer and retromer complexes, we will construct
recombinant murine coronaviruses and corona virus‐like particles with alternative motifs.
Comparisons of recombinant virus infections, along with reductionist approaches assessing the
formation and subcellular transport of virus‐like particles, will reveal how coatomer and
retromer‐sorting nexins operate in controlling viral membrane protein trafficking, virus particle
formation, and particle egress pathways. By expanding the studies to human pathogenic
coronaviruses, we expect to identify commonly utilized host machineries that might be
targeted by antiviral therapeutics.
项目总结/摘要
该提案旨在评估冠状病毒的组装和流出。这些晚期感染阶段是
相对于冠状病毒进入复制研究不足。需要进行更多的研究,
揭示了宿主细胞机制如何促进组装和出口。因此,这项建议
特别关注冠状病毒膜蛋白,它们与宿主细胞的相互作用,
组分,以及这些接触与有效病毒体形成和出现的相关性
感染的细胞。以生物化学和蛋白质结构数据为指导,记录接口
在病毒肽基序和宿主外壳体和逆转录体复合物之间,我们将构建
重组鼠冠状病毒和具有替代基序的冠状病毒样颗粒。
重组病毒感染的比较,沿着与还原主义的方法评估,
病毒样颗粒的形成和亚细胞运输,将揭示如何coatomer和
逆转录分选连接蛋白在控制病毒膜蛋白运输、病毒颗粒
形成和粒子出口路径。通过将研究扩展到人类致病性
冠状病毒,我们希望确定常用的主机,可能是
被抗病毒治疗剂靶向。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas Miller Gallagher其他文献
Thomas Miller Gallagher的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas Miller Gallagher', 18)}}的其他基金
Impacts of Adaptive Coronavirus Evolution on Viral Membrane Fusion
冠状病毒适应性进化对病毒膜融合的影响
- 批准号:
10727448 - 财政年份:2023
- 资助金额:
$ 22.23万 - 项目类别:
Entry and pathogenesis of two human coronaviruses
两种人类冠状病毒的进入和发病机制
- 批准号:
8055141 - 财政年份:2011
- 资助金额:
$ 22.23万 - 项目类别:
UBIQUITIN AND CELLULAR FACTORS IN CORONAVIRUS ASSEMBLY
冠状病毒组装中的泛素和细胞因子
- 批准号:
7646778 - 财政年份:2009
- 资助金额:
$ 22.23万 - 项目类别:
UBIQUITIN AND CELLULAR FACTORS IN CORONAVIRUS ASSEMBLY
冠状病毒组装中的泛素和细胞因子
- 批准号:
7846495 - 财政年份:2009
- 资助金额:
$ 22.23万 - 项目类别:
UBIQUITIN AND CELLULAR FACTORS IN CORONAVIRUS ASSEMBLY
冠状病毒组装中的泛素和细胞因子
- 批准号:
7860419 - 财政年份:2009
- 资助金额:
$ 22.23万 - 项目类别:
Biological Effects of SARS-CoV Spike Polymorphisms
SARS-CoV 刺突多态性的生物学效应
- 批准号:
6825526 - 财政年份:2004
- 资助金额:
$ 22.23万 - 项目类别:
Adaptive MERS coronavirus-cell entry pathways and their relevance to virulence and antiviral strategies
适应性 MERS 冠状病毒细胞进入途径及其与毒力和抗病毒策略的相关性
- 批准号:
10229391 - 财政年份:2004
- 资助金额:
$ 22.23万 - 项目类别:
Adaptive MERS coronavirus-cell entry pathways and their relevance to virulence and antiviral strategies
适应性 MERS 冠状病毒细胞进入途径及其与毒力和抗病毒策略的相关性
- 批准号:
9209899 - 财政年份:2004
- 资助金额:
$ 22.23万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 22.23万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 22.23万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 22.23万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 22.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 22.23万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 22.23万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 22.23万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 22.23万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 22.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 22.23万 - 项目类别: